Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) EBITDA Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBITDA Margin for 5 consecutive years, with 47.33% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 47.33% in Q4 2025 year-over-year; TTM through Dec 2025 was 13.51%, a N/A change, with the full-year FY2025 number at 11.0%, down 7595826.0% from a year prior.
  • EBITDA Margin was 47.33% for Q4 2025 at Soleno Therapeutics, up from 39.82% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3226.16% in Q1 2025 to a low of 39.82% in Q3 2025.